Research analysts covering MindWalk Holdings.
Recent press releases and 8-K filings for HYFT.
MindWalk Applies HYFT Technology to Detect Functional Adjacency Risk in AI-Designed Therapeutics
HYFT
Product Launch
New Projects/Investments
- MindWalk Holdings Corp. announced an application of its proprietary HYFT® technology to detect functional adjacency in AI-designed therapeutics.
- Functional adjacency, where distinct molecules produce the same biological effect despite sequence differences, is identified as a significant competitive, legal, and valuation risk in modern drug discovery.
- The HYFT technology is designed to help pharmaceutical and biotechnology organizations identify functional competitors, strengthen in-licensing and M&A diligence, inform patent strategy, and improve R&D portfolio choices by evaluating functional similarity.
- MindWalk plans to engage with pharmaceutical and biotechnology organizations for collaborations and commercial arrangements to deploy HYFT-based functional intelligence.
Jan 27, 2026, 2:31 PM
MindWalk Announces Breakthrough Discovery Targeting Neurodegenerative Disease
HYFT
New Projects/Investments
- MindWalk Holdings Corp. (Nasdaq: HYFT) announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43.
- This protein is implicated in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer's disease.
- The company states this discovery validates its platform strategy and capabilities in discriminating between toxic protein conformations and healthy counterparts, reinforcing its position as a discovery partner for complex neurodegenerative programs.
Jan 14, 2026, 3:04 PM
MindWalk Holdings Corp. Reports Q2 2026 Financial Results and Strategic Focus
HYFT
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- MindWalk Holdings Corp. reported revenue of $4.1 million for the three months ended October 31, 2025, marking a 53.9% increase from the prior year, and $7.3 million for the six months ended October 31, 2025, a 41% increase.
- The company recorded a net loss of $3.2 million for the three months ended October 31, 2025, and a net loss of $6.2 million for the six months ended October 31, 2025.
- Gross profit margin improved to 65% for the three months ended October 31, 2025, exceeding its historical range of 48-57%.
- As of October 31, 2025, cash on hand totaled $16.5 million, which is expected to fund operations for at least one year.
- MindWalk is strategically focusing on a software-led model centered on its LensAI platform and HYFT-based analytics and data services, aiming to expand subscriptions and client engagement.
Dec 15, 2025, 1:30 PM
MindWalk Holdings Corp. Reports Q2 Fiscal 2026 Financial Results and Strategic Progress
HYFT
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- MindWalk Holdings Corp. reported record revenue of $4.1 million (CAD) for the second quarter of fiscal 2026 (ended October 31, 2025), marking a 54% year-over-year increase and a 30% sequential increase.
- The company's gross margin expanded to 65% from 51% in the prior year, with gross profit increasing 94% year-over-year to $2.7 million (CAD). MindWalk ended the quarter with $16.5 million (CAD) in cash and cash equivalents, which includes $14.3 million (CAD) from the sale of its Netherlands operations.
- Strategic advancements include progress in its GLP1 & longevity program and the identification of a universal dengue vaccine epitope using its LensAI platform. The company is also establishing a new corporate structure in the Cayman Islands to house segregated portfolios for its AI-driven programs, aiming to allow direct investor participation.
- MindWalk welcomed Scott Areglado as Chief Financial Officer and Dr. Thomas Lynch as Chief Business Officer during the quarter.
Dec 15, 2025, 1:30 PM
MindWalk Holdings Corp. Appoints New CFO and Announces AGM Results
HYFT
CFO Change
Board Change
Auditor Change
- MindWalk Holdings Corp. announced the appointment of R. Scott Areglado as Chief Financial Officer, effective October 20, 2025.
- Mr. Areglado brings over 25 years of financial leadership experience from the healthcare, life sciences, and technology sectors, having previously served as CFO for BrainsWay Ltd. and iCAD, Inc..
- At its 2025 Annual General Meeting of Shareholders on October 9, 2025, Dr. Jennifer Bath, Jon Lieber, and Dirk Witters were elected to the Board of Directors, and Davidson & Company LLP was re-appointed as auditor.
- Mr. Kamil Isaev resigned from the Board, effective immediately, after his re-election bid received 68% withheld votes.
Oct 21, 2025, 1:42 PM
MindWalk Holdings Corp. Announces Share Repurchase Program
HYFT
Share Buyback
- MindWalk Holdings Corp.'s Board of Directors has authorized a share repurchase program.
- The company may repurchase up to 2.3 million common shares, representing approximately 5% of its currently issued and outstanding shares.
- The program is set to commence on October 15, 2025, and will run for a twelve-month period, ending no later than October 15, 2026.
- CEO Jennifer Bath stated that the program underscores confidence in MindWalk's future and provides flexibility to repurchase shares when the market price is believed to be disconnected from its intrinsic value.
Oct 9, 2025, 1:36 PM
MindWalk Holdings Corp. Advances AI-Designed GLP-1 Program for Longevity
HYFT
New Projects/Investments
- MindWalk Holdings Corp. announced a significant advancement in its AI-designed GLP-1 therapeutics program, introducing a first-in-class dual-pathway regimen for aging and longevity.
- The company's LensAI™ platform identified a novel connection between GLP-1 biology and a second, non-overlapping pathway, leading to the development of a proprietary companion therapeutic for co-administration with its GLP-1 receptor agonists.
- This strategic evolution positions MindWalk to target the high-growth longevity therapeutics market, which is projected to exceed $60 billion by 2030.
- MindWalk expects to provide updates on lead selection for the companion therapeutic and preclinical combination design parameters in the coming quarters.
Sep 22, 2025, 1:51 PM
MindWalk Holdings Corp. Reports Record Q1 2026 Revenue and Narrowed Losses
HYFT
Earnings
Revenue Acceleration/Inflection
M&A
- MindWalk Holdings Corp. reported record revenue of $7.6 million for its first fiscal quarter of 2026, ended July 31, 2025, representing a 45% year-over-year increase.
- The company's gross margin expanded to 53%, with gross profit reaching $4.0 million, and net loss improved to $3.0 million compared to $4.0 million in the prior year.
- MindWalk strengthened its balance sheet with a cash balance of $5.0 million at quarter-end, supplemented by $16.1 million in net proceeds from the divestiture of its Netherlands operations.
- The company completed its rebranding and advanced its dengue vaccine program into preclinical manufacturing, further validating its LensAI platform.
Sep 15, 2025, 12:51 PM
MindWalk Holdings Corp. Reports Q1 2026 Results and Completes Divestiture
HYFT
Earnings
M&A
Profit Warning
- MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) reported revenue of $3.2 million for the three months ended July 31, 2025, marking a 27.8% increase compared to the same period in 2024, alongside a net loss from continuing operations of $4.1 million.
- The company completed the divestiture of its IPA Europe B.V. on August 6, 2025, for $12 million USD, generating $11.7 million USD in net proceeds.
- As of July 31, 2025, MindWalk had $5.0 million in cash on hand and stated that this amount is insufficient to fund operations for at least one year, raising material uncertainties regarding its ability to continue as a going concern without securing additional financing.
- Management identified a material weakness in internal controls over financial reporting as of July 31, 2025, attributed to insufficient resources for complex technical accounting issues, with remediation efforts ongoing.
Sep 15, 2025, 12:51 PM
Quarterly earnings call transcripts for MindWalk Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more